Therapies in Refractory Metastatic Renal Cell Carcinoma
As the therapeutic landscape for metastatic clear cell renal cell carcinoma (mccRCC) expands to include vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immunotherapies, new challenges are in place for evaluating and treating refractory disease. Assessing and m...
Saved in:
| Main Authors: | Stephanie Berg, Martin Angel, Kathryn E. Beckermann, Frede Donskov, Chung-Han Lee, Pavlos Msaouel, Rana R. McKay, Tian Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/download/223/163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease
by: Gorka Larrinaga, et al.
Published: (2025-03-01) -
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol
by: Jakob N. Henriksen, et al.
Published: (2025-06-01) -
Targeted Therapy for Metastatic Renal Cell Carcinoma
by: Andika Afriansyah, et al.
Published: (2017-02-01) -
Targeted Therapy for Metastatic Renal Cell Carcinoma
by: Andika Afriansyah, et al.
Published: (2017-02-01) -
Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre
by: Monica Majumder, et al.
Published: (2025-06-01)